Pan Cancer T extends seed financing round
Pan Cancer T, a biotech spin-off from the Erasmus MC dedicated to the discovery and development of novel TCR-T therapies against solid tumours, has closed an extended seed investment round. All current shareholders participated in the round, with Thuja Capital joining as a new investor. The undisclosed proceeds add to